Treatment of uncomplicated urinary tract infections with trimethoprim versus sulfisoxazole, with special reference to antibody-coated bacteria and fecal flora.

Antimicrobial Agents and Chemotherapy
A IravaniH Baer

Abstract

A total of 331 college-age women with urinary tract infections were studied. These women were assigned randomly to the following groups: 50 patients treated with 400 mg of trimethoprim (TMP) per day for 14 days (designated the TMP400/14d group); 50 treated with 2.0 g of sulfisoxazole (SZ) per day for 14 days (SZ/14d group); 120 treated with 200 mg of TMP per day for 10 days (TMP200/10d group); and 111 treated with 2.0 g of SZ per day for 10 days (SZ/10d group). By the last day of therapy, clinical and bacteriological cure rates were 100% in the TMP400/14d, SZ/14d, and TMP200/10d groups and 97.1% in SZ/10d group. At 1 week after therapy ended, the initial urinary pathogens remained eradicated in 100% of the TMP400/14d group, 98.2% of the TMP200/10d group, 95.6% of the SZ/14d group, and 98.0% of the SZ/10d group at 4 weeks after therapy ended, the clinical cure rates were 92.0% in the TMP400/14d group, 92.0% in the SZ/14d group, 89.0% in the TMP200/10d group, and 90.0% in the SZ/10d group. At 4 and 24 weeks after therapy ended, the recurrence rates in the four treatment groups did not differ significantly. The antibody-coated bacteria test localized 39.5% of the infections to kidneys and 56.8% of the infections to bladders. Neith...Continue Reading

References

Apr 1, 1977·The Journal of Infectious Diseases·J W SmithB Kaijser
Jun 16, 1978·JAMA : the Journal of the American Medical Association·C M KuninD T Uehling
Sep 8, 1978·JAMA : the Journal of the American Medical Association·G K HardingP Muir
Apr 1, 1978·Journal of Clinical Pathology·W A GillespieA L Hilton
Sep 1, 1976·Acta paediatrica Scandinavica·U ForsumG Jonsell
Mar 14, 1974·The New England Journal of Medicine·S R JonesJ P Sanford
May 1, 1974·The Journal of Urology·M D Cosgrove, J W Morrow
Aug 15, 1974·The New England Journal of Medicine·S R Jones
May 1, 1968·British Journal of Pharmacology and Chemotherapy·S R Bushby, G H Hitchings
Mar 1, 1968·Journal of Clinical Pathology·J H DarrellP M Waterworth
Oct 1, 1980·The Journal of Infectious Diseases·P A JordanH Baer
Dec 1, 1958·Journal of Chronic Diseases·S J CUTLER, F EDERER
Sep 1, 1962·The Journal of Clinical Investigation·M TURCK, R G PETERSDORF

❮ Previous
Next ❯

Citations

Sep 1, 1992·Journal of General Internal Medicine·A G PinsonJ B Schorling
Aug 29, 2001·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D Steinke, P Davey
Oct 1, 1982·Antimicrobial Agents and Chemotherapy·A Iravani, G A Richard
Aug 1, 1985·Antimicrobial Agents and Chemotherapy·P HuovinenP Toivanen
Aug 1, 1989·Antimicrobial Agents and Chemotherapy·T M HootonW E Stamm
Apr 1, 1991·Antimicrobial Agents and Chemotherapy·A Iravani
Jun 22, 1992·The American Journal of Medicine·A Iravani, W Bischoff
Nov 8, 2005·The American Journal of Medicine·Eugene A KatchmanLeonard Leibovici
Jan 4, 2017·Médecine et maladies infectieuses·F CaronM Etienne
Sep 1, 1983·The Journal of Urology·A IravaniG A Richard
Jan 5, 2021·Toxicological Sciences : an Official Journal of the Society of Toxicology·Yanshan CaoJack Uetrecht

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.